Skip to main content
Part of Sickle Cell Disease on Somebody To Talk To

Sickle Cell Disease clinical trials near you

A clinical trial is a research study that tests whether a treatment is safe and works. Taking part is always your choice, and you can stop at any time. Listing a study here is not a recommendation — talk it through with your own team.

138 recruiting studiesFrom ClinicalTrials.gov (opens in a new tab)

Trial results

8 shown of 138

8 shown of 138 clinical trials.

  1. RecruitingObservationalNCT06385886

    Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

    Sickle Cell Disease

    The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once unaffiliated individuals are found using the pathways, Investigators will employ linkage coordinators (trained staff) to engage these patients in care. Participants will be asked to fill out an assessment survey which will cover areas such as previous and current treatment, clinic and hospital experience, pain, and quality of life. Participants will also be given the option of participation in a 1-hour long interview how they feel about treatment for sickle cell disease including clinic experience, pain, and quality of life?

    Sites
    9
    Target
    500
    Study sites
    Birmingham, US +8 more

    Sponsor: RTI International

    View on ClinicalTrials.gov(opens in a new tab)
  2. RecruitingPhase 1, Phase 2InterventionalNCT03128996

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

    Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders

    This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.

    Sites
    4
    Target
    29
    Study sites
    New Haven, US +3 more

    Sponsor: Washington University School of Medicine

    View on ClinicalTrials.gov(opens in a new tab)
  3. RecruitingPhase 3InterventionalNCT05392894

    RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease

    Sickle Cell Disease

    The purpose of this clinical trial is to evaluate the clinical and cost effectiveness of Haploidentical Stem Cell Transplantation (SCT) for adults with severe sickle cell disease (SCD), who have failed other therapies or are intolerant of existing therapies or require chronic transfusions to prevent on-going complications of SCD.

    Sites
    1
    Target
    120
    Study sites
    London, GB

    Sponsor: King's College Hospital NHS Trust

    View on ClinicalTrials.gov(opens in a new tab)
  4. RecruitingPhase 2InterventionalNCT05583721

    Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET

    Sickle Cell Disease

    There is limited information on what causes injury to the heart in individuals with Sickle Cell Disease (SCD). Researchers in this study want to see if decreased blood flow to the heart during stress could be causing the heart damage seen in SCD patients. They also want to test people who don't have SCD to see if their hearts react the same way under stress. Primary Objective * To estimate the coronary flow reserve (CFR) (also referred to as myocardial perfusion reserve), as measured by PET stress-rest myocardial perfusion imaging, in SCD patients with and without diastolic dysfunction, and healthy controls. Secondary Objectives * To investigate the relationship between decreased CFR (quantified with PET stress- rest myocardial perfusion imaging) and presence of abnormal diastolic parameters

    Sites
    1
    Target
    40
    Study sites
    Memphis, US

    Sponsor: St. Jude Children's Research Hospital

    View on ClinicalTrials.gov(opens in a new tab)
  5. RecruitingPhase 4InterventionalNCT04657822

    Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

    Sickle Cell Disease

    This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

    Sites
    31
    Target
    130
    Study sites
    Birmingham, US +30 more

    Sponsor: Novartis Pharmaceuticals

    View on ClinicalTrials.gov(opens in a new tab)
  6. RecruitingPhase 1, Phase 2InterventionalNCT07252050

    Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

    Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant, Haploidentical Stem Cell Transplantation, Graft Failure

    This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT.

    Sites
    4
    Target
    24
    Study sites
    Aurora, US +3 more

    Sponsor: Arkansas Children's Hospital Research Institute

    View on ClinicalTrials.gov(opens in a new tab)
  7. RecruitingPhase 2InterventionalNCT07224360

    Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

    Sickle Cell Disease

    This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.

    Sites
    16
    Target
    63
    Study sites
    Little Rock, US +15 more

    Sponsor: CSL Behring

    View on ClinicalTrials.gov(opens in a new tab)
  8. RecruitingPhase 2InterventionalNCT06699849

    Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

    Sickle Cell Disease Vaso-occlusive Crisis

    This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to evaluate the safety and tolerability of CSL889 in study participants, and to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD.

    Sites
    30
    Target
    70
    Study sites
    Oakland, US +29 more

    Sponsor: CSL Behring

    View on ClinicalTrials.gov(opens in a new tab)